New insights into IGF-1 signaling in the heart

Trends in Endocrinology and Metabolism

Volumn 25, Issue 3, 2014, Pages 128-137

  Troncoso, Rodrigo ^a   Ibarra, Cristián ^b   Vicencio, Jose Miguel ^c   Jaimovich, Enrique ^a   Lavandero, Sergio ^a,d  

^a UNIVERSITY OF CHILE   (Chile)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Calcium; Cardiac progenitor stem cells; IGF 1R; Inter organelle communication

Indexed keywords

CALCIUM; CARDIAC PROGENITOR STEM CELLS; IGF-1R; INTER-ORGANELLE COMMUNICATION;

CALCIUM; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIUM; PHOSPHORYLATION; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; STEM CELLS;

EID: 84894364992     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2013.12.002     Document Type: Review

References (115)

1. De Meyts P., Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat. Rev. Drug Discov. 2002, 1:769-783.
2. Saetrum Opgaard O., Wang P.H. IGF-I is a matter of heart. Growth Horm. IGF Res. 2005, 15:89-94.
3. Ungvari Z., Csiszar A. The emerging role of IGF-1 deficiency in cardiovascular aging: recent advances. J. Gerontol. A: Biol. Sci. Med. Sci. 2012, 67:599-610.
4. Troncoso R., et al. Regulation of cardiac autophagy by insulin-like growth factor 1. IUBMB Life 2013, 65:593-601.
5. Hausenloy D.J., Yellon D.M. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J. Clin. Invest. 2013, 123:92-100.
6. Go A.S., et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation 2013, 127:e6-e245.
7. Puche J.E., Castilla-Cortazar I. Human conditions of insulin-like growth factor-I (IGF-I) deficiency. J. Transl. Med. 2012, 10:224.
8. Spallarossa P., et al. Insulin-like growth factor-I and angiographically documented coronary artery disease. Am. J. Cardiol. 1996, 77:200-202.
9. Johnsen S.P., et al. Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke. J. Clin. Endocrinol. Metab. 2005, 90:5937-5941.
10. Vasan R.S., et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann. Intern. Med. 2003, 139:642-648.
11. Watanabe S., et al. Insulin-like growth factor axis (insulin-like growth factor-I/insulin-like growth factor-binding protein-3) as a prognostic predictor of heart failure: association with adiponectin. Eur. J. Heart Fail. 2010, 12:1214-1222.
12. Troncoso R., et al. Energy-preserving effects of IGF-1 antagonize starvation-induced cardiac autophagy. Cardiovasc. Res. 2012, 93:320-329.
13. Eisner V., et al. Hyperosmotic stress-dependent NFkappaB activation is regulated by reactive oxygen species and IGF-1 in cultured cardiomyocytes. FEBS Lett. 2006, 580:4495-4500.
14. Zhang Y., et al. Insulin-like growth factor 1 alleviates high-fat diet-induced myocardial contractile dysfunction: role of insulin signaling and mitochondrial function. Hypertension 2012, 59:680-693.
15. Perkel D., et al. The potential effects of IGF-1 and GH on patients with chronic heart failure. J. Cardiovasc. Pharmacol. Ther. 2012, 17:72-78.
16. Fontana L., et al. Growth factors, nutrient signaling, and cardiovascular aging. Circ. Res. 2012, 110:1139-1150.
17. Higashi Y., et al. Aging, atherosclerosis, and IGF-1. J. Gerontol. A: Biol. Sci. Med. Sci. 2012, 67:626-639.
18. Adams T.E., et al. Structure and function of the type 1 insulin-like growth factor receptor. Cell. Mol. Life Sci. 2000, 57:1050-1093.
19. Jacobs S., et al. Monensin blocks the maturation of receptors for insulin and somatomedin C: identification of receptor precursors. Proc. Natl. Acad. Sci. U.S.A. 1983, 80:1228-1231.
20. Ibarra C., et al. Local control of nuclear calcium signaling in cardiac myocytes by perinuclear microdomains of sarcolemmal insulin-like growth factor 1 receptors. Circ. Res. 2013, 112:236-245.
21. Foncea R., et al. Insulin-like growth factor-I rapidly activates multiple signal transduction pathways in cultured rat cardiac myocytes. J. Biol. Chem. 1997, 272:19115-19124.
22. Ward C.W., et al. The three dimensional structure of the type I insulin-like growth factor receptor. Mol. Pathol. 2001, 54:125-132.
23. Kim J., et al. Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy. Mol. Endocrinol. 2008, 22:2531-2543.
24. Foncea R., et al. Extracellular regulated kinase, but not protein kinase C, is an antiapoptotic signal of insulin-like growth factor-1 on cultured cardiac myocytes. Biochem. Biophys. Res. Commun. 2000, 273:736-744.
25. Dalle S., et al. Insulin and insulin-like growth factor I receptors utilize different G protein signaling components. J. Biol. Chem. 2001, 276:15688-15695.
26. Hallak H., et al. Association of heterotrimeric G(i) with the insulin-like growth factor-I receptor. Release of G(betagamma) subunits upon receptor activation. J. Biol. Chem. 2000, 275:2255-2258.
27. Kuemmerle J.F., Murthy K.S. Coupling of the insulin-like growth factor-I receptor tyrosine kinase to Gi2 in human intestinal smooth muscle: Gbetagamma-dependent mitogen-activated protein kinase activation and growth. J. Biol. Chem. 2001, 276:7187-7194.
28. Luttrell L.M., et al. G beta gamma subunits mediate mitogen-activated protein kinase activation by the tyrosine kinase insulin-like growth factor 1 receptor. J. Biol. Chem. 1995, 270:16495-16498.
29. Ibarra C., et al. Insulin-like growth factor-1 induces an inositol 1,4,5-trisphosphate-dependent increase in nuclear and cytosolic calcium in cultured rat cardiac myocytes. J. Biol. Chem. 2004, 279:7554-7565.
30. Tadevosyan A., et al. G protein-coupled receptor signalling in the cardiac nuclear membrane: evidence and possible roles in physiological and pathophysiological function. J. Physiol. 2012, 590:1313-1330.
31. Merlen C., et al. Intracrine endothelin signaling evokes IP3-dependent increases in nucleoplasmic Ca in adult cardiac myocytes. J. Mol. Cell. Cardiol. 2013, 62C:189-202.
32. Tadevosyan A., et al. Nuclear-delimited angiotensin receptor-mediated signaling regulates cardiomyocyte gene expression. J. Biol. Chem. 2010, 285:22338-22349.
33. Vaniotis G., et al. Nuclear beta-adrenergic receptors modulate gene expression in adult rat heart. Cell. Signal. 2011, 23:89-98.
34. Nikolaev V.O., et al. Beta2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation. Science 2010, 327:1653-1657.
35. Lyon A.R., et al. Loss of T-tubules and other changes to surface topography in ventricular myocytes from failing human and rat heart. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:6854-6859.
36. Bers D.M. Membrane receptor neighborhoods: snuggling up to the nucleus. Circ. Res. 2013, 112:224-226.
37. Arantes L.A., et al. Nuclear inositol 1,4,5-trisphosphate is a necessary and conserved signal for the induction of both pathological and physiological cardiomyocyte hypertrophy. J. Mol. Cell. Cardiol. 2012, 53:475-486.
38. Lyon A.R., et al. Plasticity of surface structures and beta(2)-adrenergic receptor localization in failing ventricular cardiomyocytes during recovery from heart failure. Circ. Heart Fail. 2012, 5:357-365.
39. Chiong M., et al. Cardiomyocyte death: mechanisms and translational implications. Cell Death Dis. 2011, 2:e244.
40. Mehrhof F.B., et al. In cardiomyocyte hypoxia, insulin-like growth factor-I-induced antiapoptotic signaling requires phosphatidylinositol-3-OH-kinase-dependent and mitogen-activated protein kinase-dependent activation of the transcription factor cAMP response element-binding protein. Circulation 2001, 104:2088-2094.
41. Kurmasheva R.T., Houghton P.J. IGF-I mediated survival pathways in normal and malignant cells. Biochim. Biophys. Acta 2006, 1766:1-22.
42. Wang J., et al. Effects of Igf1 gene deletion on postnatal growth patterns. Endocrinology 1999, 140:3391-3394.
43. Glass D.J. Skeletal muscle hypertrophy and atrophy signaling pathways. Int. J. Biochem. Cell Biol. 2005, 37:1974-1984.
44. Song Y.H., et al. Insulin-like growth factor I-mediated skeletal muscle hypertrophy is characterized by increased mTOR-p70S6K signaling without increased Akt phosphorylation. J. Investig. Med. 2005, 53:135-142.
45. Lavandero S., et al. Effect of inhibitors of signal transduction on IGF-1-induced protein synthesis associated with hypertrophy in cultured neonatal rat ventricular myocytes. FEBS Lett. 1998, 422:193-196.
46. Nakayama H., et al. The IP3 receptor regulates cardiac hypertrophy in response to select stimuli. Circ. Res. 2010, 107:659-666.
47. Ham Y.M., Mahoney S.J. Compensation of the AKT signaling by ERK signaling in transgenic mice hearts overexpressing TRIM72. Exp. Cell Res. 2013, 319:1451-1462.
48. McMullen J.R., et al. The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway. J. Biol. Chem. 2004, 279:4782-4793.
49. Delaughter M.C., et al. Local insulin-like growth factor I expression induces physiologic, then pathologic, cardiac hypertrophy in transgenic mice. FASEB J. 1999, 13:1923-1929.
50. Choi A.M., et al. Autophagy in human health and disease. N. Engl. J. Med. 2013, 368:1845-1846.
51. Lavandero S., et al. Cardiovascular autophagy: Concepts, controversies and perspectives. Autophagy 2013, 9:1455-1466.
52. Rothermel B.A., Hill J.A. Myocyte autophagy in heart disease: friend or foe?. Autophagy 2007, 3:632-634.
53. Matsui Y., et al. Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circ. Res. 2007, 100:914-922.
54. Zhu H., et al. Cardiac autophagy is a maladaptive response to hemodynamic stress. J. Clin. Invest. 2007, 117:1782-1793.
55. Bitto A., et al. Long-term IGF-I exposure decreases autophagy and cell viability. PLoS ONE 2010, 5:e12592.
56. Jia G., et al. Insulin-like growth factor-1 and TNF-alpha regulate autophagy through c-jun N-terminal kinase and Akt pathways in human atherosclerotic vascular smooth cells. Immunol. Cell Biol. 2006, 84:448-454.
57. DeBosch B.J., Muslin A.J. Insulin signaling pathways and cardiac growth. J. Mol. Cell. Cardiol. 2008, 44:855-864.
58. Nagoshi T., et al. Optimization of cardiac metabolism in heart failure. Curr. Pharm. Des. 2011, 17:3846-3853.
59. Muslin A.J. Akt2: a critical regulator of cardiomyocyte survival and metabolism. Pediatr. Cardiol. 2011, 32:317-322.
60. Bailyes E.M., et al. Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem. J. 1997, 327:209-215.
61. Slaaby R., et al. Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant. J. Biol. Chem. 2006, 281:25869-25874.
62. Soos M.A., et al. Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochem. J. 1993, 290:419-426.
63. Pierre-Eugene C., et al. Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2. PLoS ONE 2012, 7:e41992.
64. Belfiore A., et al. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr. Rev. 2009, 30:586-623.
65. Federici M., et al. Expression of insulin/IGF-I hybrid receptors is increased in skeletal muscle of patients with chronic primary hyperinsulinemia. Diabetes 1998, 47:87-92.
66. Federici M., et al. Increased abundance of insulin/insulin-like growth factor-I hybrid receptors in skeletal muscle of obese subjects is correlated with in vivo insulin sensitivity. J. Clin. Endocrinol. Metab. 1998, 83:2911-2915.
67. Simpson H.L., et al. Insulin-like growth factor I has a direct effect on glucose and protein metabolism, but no effect on lipid metabolism in type 1 diabetes. J. Clin. Endocrinol. Metab. 2004, 89:425-432.
68. Kolaczynski J.W., Caro J.F. Insulin-like growth factor-1 therapy in diabetes: physiologic basis, clinical benefits, and risks. Ann. Intern. Med. 1994, 120:47-55.
69. Moses A.C. Insulin resistance and type 2 diabetes mellitus: is there a therapeutic role for IGF-1?. Endocr. Dev. 2005, 9:121-134.
70. Marsh S.A., Davidoff A.J. Heart smart insulin-like growth factor 1. Hypertension 2012, 59:550-551.
71. Scharin Tang M., et al. Importance of circulating IGF-1 for normal cardiac morphology, function and post infarction remodeling. Growth Horm. IGF Res. 2012, 22:206-211.
72. Guevara-Aguirre J., et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci. Transl. Med. 2011, 3:70ra13.
73. Scheinowitz M., et al. IGF-I replacement therapy in children with congenital IGF-I deficiency (Laron syndrome) maintains heart dimension and function. Growth Horm. IGF Res. 2009, 19:280-282.
74. Panici J.A., et al. Early life growth hormone treatment shortens longevity and decreases cellular stress resistance in long-lived mutant mice. FASEB J. 2010, 24:5073-5079.
75. Sonntag W.E., et al. Adult-onset growth hormone and insulin-like growth factor I deficiency reduces neoplastic disease, modifies age-related pathology, and increases life span. Endocrinology 2005, 146:2920-2932.
76. Groban L., et al. Early-onset growth hormone deficiency results in diastolic dysfunction in adult-life and is prevented by growth hormone supplementation. Growth Horm. IGF Res. 2011, 21:81-88.
77. Li Q., et al. Deficiency of insulin-like growth factor 1 reduces sensitivity to aging-associated cardiomyocyte dysfunction. Rejuvenation Res. 2008, 11:725-733.
78. Hua Y., et al. IGF-1 deficiency resists cardiac hypertrophy and myocardial contractile dysfunction: role of microRNA-1 and microRNA-133a. J. Cell. Mol. Med. 2012, 16:83-95.
79. Bailey-Downs L.C., et al. Liver-specific knockdown of IGF-1 decreases vascular oxidative stress resistance by impairing the Nrf2-dependent antioxidant response: a novel model of vascular aging. J. Gerontol. A: Biol. Sci. Med. Sci. 2012, 67:313-329.
80. Fernandes C.J., de Assuncao M.S. Myocardial dysfunction in sepsis: a large, unsolved puzzle. Crit. Care Res. Pract. 2012, 2012:896430.
81. Rudiger A., Singer M. Mechanisms of sepsis-induced cardiac dysfunction. Crit. Care Med. 2007, 35:1599-1608.
82. Romero-Bermejo F.J., et al. Sepsis-induced cardiomyopathy. Curr. Cardiol. Rev. 2011, 7:163-183.
83. Ashare A., et al. Insulin-like growth factor-1 improves survival in sepsis via enhanced hepatic bacterial clearance. Am. J. Respir. Crit. Care Med. 2008, 178:149-157.
84. Schmitz D., et al. Survival and cellular immune functions in septic mice treated with growth hormone (GH) and insulin-like growth factor-I (IGF-I). Growth Horm. IGF Res. 2008, 18:245-252.
85. Zhao P., et al. Cardiac-specific overexpression of insulin-like growth factor I (IGF-1) rescues lipopolysaccharide-induced cardiac dysfunction and activation of stress signaling in murine cardiomyocytes. Shock 2009, 32:100-107.
86. Nystrom G., et al. Local insulin-like growth factor I prevents sepsis-induced muscle atrophy. Metabolism 2009, 58:787-797.
87. Philippou A., et al. Type I insulin-like growth factor receptor signaling in skeletal muscle regeneration and hypertrophy. J. Musculoskelet. Neuronal Interact. 2007, 7:208-218.
88. Kawai M., Rosen C.J. Insulin-like growth factor-I and bone: lessons from mice and men. Pediatr. Nephrol. 2009, 24:1277-1285.
89. Aberg N.D., et al. Aspects of growth hormone and insulin-like growth factor-I related to neuroprotection, regeneration, and functional plasticity in the adult brain. Sci. World J. 2006, 6:53-80.
90. Anversa P., et al. Regenerating new heart with stem cells. J. Clin. Invest. 2013, 123:62-70.
91. Bostrom P., Frisen J. New cells in old hearts. N. Engl. J. Med. 2013, 368:1358-1360.
92. Senyo S.E., et al. Mammalian heart renewal by pre-existing cardiomyocytes. Nature 2013, 493:433-436.
93. Garbern J.C., Lee R.T. Cardiac stem cell therapy and the promise of heart regeneration. Cell Stem Cell 2013, 12:689-698.
94. Hsieh P.C., et al. Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat. Med. 2007, 13:970-974.
95. Loffredo F.S., et al. Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. Cell Stem Cell 2011, 8:389-398.
96. Segers V.F., Lee R.T. Protein therapeutics for cardiac regeneration after myocardial infarction. J. Cardiovasc. Transl. Res. 2010, 3:469-477.
97. Yu X.Y., et al. The effects of mesenchymal stem cells on c-kit up-regulation and cell-cycle re-entry of neonatal cardiomyocytes are mediated by activation of insulin-like growth factor 1 receptor. Mol. Cell. Biochem. 2009, 332:25-32.
98. Beltrami A.P., et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003, 114:763-776.
99. Kawaguchi N., et al. c-kitpos GATA-4 high rat cardiac stem cells foster adult cardiomyocyte survival through IGF-1 paracrine signalling. PLoS ONE 2010, 5:e14297.
100. D'Amario D., et al. Insulin-like growth factor-1 receptor identifies a pool of human cardiac stem cells with superior therapeutic potential for myocardial regeneration. Circ. Res. 2011, 108:1467-1481.
101. Wetterau L.A., et al. Insulin-like growth factor I stimulates telomerase activity in prostate cancer cells. J. Clin. Endocrinol. Metab. 2003, 88:3354-3359.
102. Linke A., et al. Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:8966-8971.
103. Urbanek K., et al. Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circ. Res. 2005, 97:663-673.
104. Rota M., et al. Local activation or implantation of cardiac progenitor cells rescues scarred infarcted myocardium improving cardiac function. Circ. Res. 2008, 103:107-116.
105. Davis M.E., et al. Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:8155-8160.
106. Genead R., et al. Ischemia-reperfusion injury and pregnancy initiate time-dependent and robust signs of up-regulation of cardiac progenitor cells. PLoS ONE 2012, 7:e36804.
107. Ellison G.M., et al. Adult c-kit(pos) cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repair. Cell 2013, 154:827-842.
108. Ferreira-Martins J., et al. Spontaneous calcium oscillations regulate human cardiac progenitor cell growth. Circ. Res. 2009, 105:764-774.
109. Fatma S., et al. Factors released from embryonic stem cells stimulate c-kit-FLK-1(+ve) progenitor cells and enhance neovascularization. Antioxid. Redox Signal. 2010, 13:1857-1865.
110. Enoki C., et al. Enhanced mesenchymal cell engraftment by IGF-1 improves left ventricular function in rats undergoing myocardial infarction. Int. J. Cardiol. 2010, 138:9-18.
111. Hahn J.Y., et al. Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J. Am. Coll. Cardiol. 2008, 51:933-943.
112. Gallagher E.J., LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol. Metab. 2010, 21:610-618.
113. Huynh K., et al. Cardiac-specific IGF-1 receptor transgenic expression protects against cardiac fibrosis and diastolic dysfunction in a mouse model of diabetic cardiomyopathy. Diabetes 2010, 59:1512-1520.
114. Vinciguerra M., et al. Local IGF-1 isoform protects cardiomyocytes from hypertrophic and oxidative stresses via SirT1 activity. Aging 2010, 2:43-62.
115. Vinciguerra M., et al. mIGF-1/JNK1/SirT1 signaling confers protection against oxidative stress in the heart. Aging Cell 2012, 11:139-149.